Val Delp

Val Delp

Counsel Corporate & Finance

Philadelphia

+1 267 675 4649

[email protected]

Val Delp

Overview
Experience
Credentials
Insights and events

Val helps public companies tackle a broad range of complex securities and corporate matters impacting day-to-day and strategic operations.

Public companies rely on Val to help them navigate the ever-evolving landscape of SEC reporting, securities law compliance and corporate governance. She advises management and boards of directors on SEC disclosure obligations, compliance with NYSE and Nasdaq rules, and shareholder engagement and activism. Val also has a proven record of effectively counseling clients on securities and corporate issues in a range of transactions, including mergers, acquisitions, spin-offs, public and private offerings, restructurings and global reorganizations.

Val maintains a diverse pro bono practice, including representing asylum seekers and assisting nonprofits with governance issues.

Before joining Hogan Lovells, Val worked in the Washington, D.C. office of another leading international law firm where she advised clients on a range of corporate and securities matters.

Prior to practicing law, Val worked in both the U.S. Senate and U.S. House of Representatives and spent several election cycles developing and implementing fundraising strategies on political campaigns.

Representative experience

Sesen Bio (NASDAQ:SESN), a clinical stage biopharmaceutical company, on its reverse merger with Carisma Therapeutics, a biopharmaceutical company focusing on cellular immunotherapy.

Urstadt Biddle Properties Inc. (NYSE:UBP) on its sale to Regency Centers Corporation in an all-stock transaction valued at US$1.4B.

Conformis, Inc. (NASDAQ:CFMS) on its sale to restor3d, Inc. in an all-cash transaction.

Marvell Technology Group (NASDAQ:MRVL) on its US$10bn acquisition of Inphi (NYSE: IPHI) in a cash-and-stock transaction.

Rosetta Stone (NYSE:RST) on its US$792m sale to Cambium Learning Group in an all-cash transaction.

Dialog Semiconductor (XETRA:DLG) in its US$500m acquisition of Adesto Technologies (NASDAQ: IOTS).

A clinical-stage pharmaceutical company in various at-the-market equity offerings led by Jefferies.

A commercial-stage pharmaceutical company in its US$46m follow-on public offering of common stock led by Piper Sandler and Cantor.

A clinical-stage pharmaceutical company in a registered direct offering and concurrent private placement.

A worldwide leader in automotive safety during an internal reorganization and spin-off of its active safety technology business into a new publicly traded company.*

A privately held global producer of audio products, electronics, and software in a cross-border reorganization.*

*Matter handled prior to joining Hogan Lovells.